IKBKB gain of function: An inborn error with clinical heterogeneity progressing toward combined immunodeficiency
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2025.04.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Julia Körholz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic…. Hauptthemen laut MEDLINE: I-kappa B Kinase, Gain of Function Mutation, B-Lymphocytes, T-Lymphocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Immunodeficiencies Amsterdam, University of Zurich, Else Kroner-Fresenius Foundation.
Abstract (Originalsprache)
BACKGROUND: The nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway is a key regulator of immune responses, cell survival, and proliferation. Dysregulation of this signaling pathway is implicated in various human diseases, including inborn errors of immunity. OBJECTIVE: We describe the clinical heterogeneity in 16 patients from 4 unrelated families with missense variants in the kinase domain of IKK2 encoded by IKBKB. METHODS: Genetic variants (p.V203I and p.M65T) in the patients were identified by whole-exome sequencing. An NF-κB reporter assay was performed to investigate NF-κB activity. Extensive immunophenotyping, a lymphocyte proliferation assay, and signaling pathway analysis were performed to gain biological insight into the impact on B- and T-cell phenotype and function. RESULTS: Whole-exome sequencing revealed 2 gain-of-function variants in the IKBKB gene, of which one was a novel variant. While lymphocyte cell numbers are generally normal at young ages, most adult patients exhibit strongly reduced B- and T-cell numbers. Although still normal in their proliferative capacity, B and T cells show defective activation at day 3 (CD70, CD25, and CD40L expression) and impaired B-cell differentiation into plasmablasts. Altered NF-κB signaling was evidenced by phosphoflow experiments. These findings coincide with autoinflammatory skin manifestations, systemic infections with progressive lymphopenia, and potentially fatal diseases occurring later in life. CONCLUSION: This study broadens the clinical spectrum of IKBKB gain-of-function variants as a progressive immunodeficiency in adulthood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address: Julia.koerholz@ukdd.de.
- Department of Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Experimental Imm…
- Erasmus MC, University Medical Center Rotterdam, Department of Clinical Genetics, Erasmus, The Netherlands.
- Erasmus MC, University Medical Center Rotterdam, Laboratory Medical Immunology, Department of Immunology, Erasmus, The Netherlands.
- Department of Internal Medicine, Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Laboratory Medicine, Laborat…
Förderung
- Center for Immunodeficiencies Amsterdam
- University of Zurich
- Else Kroner-Fresenius Foundation
- Eva Luise and Horst Köhler Foundation for Rare Diseases
- Federal Ministry of Education and Research Bonn Office
- Swiss National Science Foundation
Zitieren
APA
Körholz, J., Tromp, S. A. M., Dalm, V. A. S. H., de Bie, M., de Bree, G. J., van Leeuwen, E. M. M., Fraaij, P. L. A., Jansen, M. H., Hollink, I. H. I. M., Nagelkerke, S. Q., Russ, S., Scholze, A. K., Soomann, M., Wiedemuth, R., Pachlopnik Schmid, J., Hanitsch, L. G., Schuetz, C., Kuijpers, T. W., & IJspeert, H. (2025). IKBKB gain of function: An inborn error with clinical heterogeneity progressing toward combined immunodeficiency. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.04.033
Vancouver
Körholz J, Tromp SAM, Dalm VASH, de Bie M, de Bree GJ, van Leeuwen EMM, et al. IKBKB gain of function: An inborn error with clinical heterogeneity progressing toward combined immunodeficiency. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.04.033
BibTeX
@article{Krholz2025,
author = {Körholz, Julia and Tromp, Samantha A M and Dalm, Virgil A S H and de Bie, Maaike and de Bree, Godelieve J and van Leeuwen, Ester M M and Fraaij, Pieter L A and Jansen, Machiel H and Hollink, Iris H I M and Nagelkerke, Sietse Q and Russ, Susanne and Scholze, Anne-Kathleen and Soomann, Maarja and Wiedemuth, Ralf and Pachlopnik Schmid, Jana and Hanitsch, Leif G and Schuetz, Catharina and Kuijpers, Taco W and IJspeert, Hanna},
title = {IKBKB gain of function: An inborn error with clinical heterogeneity progressing toward combined immunodeficiency},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2025.04.033}
}
EUVIMED